共 181 条
[101]
Schwab U(2017)Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma Blood 130 1375-3765
[102]
Ellis TM(2018)Brentuximab Vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma N Engl J Med 378 331-566
[103]
Stein H(2015)Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma Blood 126 3982-1402
[104]
Feller AC(2018)Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial Lancet Oncol 19 257-1384
[105]
Sterry W(2014)Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin Blood 123 3095-1967
[106]
Hu S(2015)Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome JAMA Dermatol 151 73-1337
[107]
Kaudewitz P(2015)Phase II investigator-initiated study of Brentuximab Vedotin in mycosis Fungoides and Sezary syndrome with variable CD30 expression level: a multi-institution collaborative project J Clin Oncol 33 3750-11
[108]
Blatt K(2015)Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis J Clin Oncol 33 3759-2471
[109]
Gerli R(2017)Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial Lancet 390 555-2897
[110]
Ihn H(2015)Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Blood 125 1394-1194